STOCK TITAN

RenovoRx Announces First Patient Enrolled at University of Nebraska Medical Center for the Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)

RenovoRx (Nasdaq: RNXT) has announced the enrollment of the first patient at the University of Nebraska Medical Center (UNMC) for its ongoing Phase III TIGeR-PaC clinical trial. The study is evaluating RenovoGem™, a novel therapy for Locally Advanced Pancreatic Cancer (LAPC) using the TAMP™ (Trans-Arterial Micro-Perfusion) platform. This approach aims to deliver gemcitabine chemotherapy directly to the tumor site, potentially overcoming the challenge of drug penetration through the tumor's protective scar tissue.

The trial compares TAMP therapy to standard intravenous chemotherapy. UNMC, which joined the study in June 2024, is expected to help drive enrollment to completion by next year. The TIGeR-PaC study is currently enrolling unresectable LAPC patients across multiple US sites, reflecting RenovoRx's commitment to improving outcomes for patients with difficult-to-treat pancreatic cancer.

RenovoRx (Nasdaq: RNXT) ha annunciato l'arruolamento del primo paziente presso il University of Nebraska Medical Center (UNMC) per il suo attuale trial clinico di Fase III TIGeR-PaC. Lo studio sta valutando RenovoGem™, una nuova terapia per il cancro pancreatico localmente avanzato (LAPC) utilizzando la piattaforma TAMP™ (Micro-perfusione trans-arteriosa). Questo approccio mira a somministrare la chemioterapia con gemcitabina direttamente al sito tumorale, potenzialmente superando la sfida della penetrazione del farmaco attraverso il tessuto cicatriziale protettivo del tumore.

Il trial confronta la terapia TAMP con la chemioterapia endovenosa standard. L'UNMC, che ha aderito allo studio nel giugno 2024, ci si aspetta che contribuisca a portare a termine l'arruolamento entro il prossimo anno. Lo studio TIGeR-PaC attualmente sta arruolando pazienti con LAPC non operabili in diversi siti degli Stati Uniti, riflettendo l'impegno di RenovoRx nel migliorare i risultati per i pazienti con cancro pancreatico difficile da trattare.

RenovoRx (Nasdaq: RNXT) ha anunciado la inclusión del primer paciente en el University of Nebraska Medical Center (UNMC) para su actual ensayo clínico Fase III TIGeR-PaC. El estudio está evaluando RenovoGem™, una nueva terapia para el cáncer de páncreas localmente avanzado (LAPC) utilizando la plataforma TAMP™ (Microperfusión Transarterial). Este enfoque tiene como objetivo administrar la quimioterapia con gemcitabina directamente en el sitio del tumor, superando potencialmente el desafío de la penetración del fármaco a través del tejido cicatrizante protector del tumor.

El ensayo compara la terapia TAMP con la quimioterapia intravenosa estándar. Se espera que el UNMC, que se unió al estudio en junio de 2024, ayude a completar la inscripción para el próximo año. El estudio TIGeR-PaC está actualmente reclutando pacientes con LAPC no reseccionable en varios sitios de EE. UU., lo que refleja el compromiso de RenovoRx de mejorar los resultados para pacientes con cáncer pancreático de difícil tratamiento.

RenovoRx(Nasdaq: RNXT)는 네브래스카대학교 의과대학(UNMC)에서 진행 중인 3상 TIGeR-PaC 임상 시험의 첫 번째 환자 등록을 발표했습니다. 이 연구는 TAMP™(경동맥 미세관류) 플랫폼을 사용하여 국소 진행성 췌장암(LAPC)에 대한 새로운 치료법인 RenovoGem™을 평가하고 있습니다. 이 접근법은Gemcitabine 화학 요법을 종양 부위에 직접 전달하는 것을 목표로 하여, 종양의 보호 흉터 조직을 통한 약물 침투 문제를 극복할 수 있는 가능성을 가지고 있습니다.

이 시험은 TAMP 요법을 표준 정맥 주사 화학 요법과 비교하고 있습니다. UNMC는 2024년 6월에 연구에 참여했으며, 내년까지 선정 완료를 도와줄 것으로 기대됩니다. TIGeR-PaC 연구는 현재 여러 미국 사이트에서 절제 불가능한 LAPC 환자를 등록하고 있으며, 이는 RenovoRx가 치료하기 어려운 췌장암 환자들의 결과를 개선하려는 의지를 반영합니다.

RenovoRx (Nasdaq: RNXT) a annoncé l'enrôlement du premier patient au University of Nebraska Medical Center (UNMC) pour son essai clinique de Phase III TIGeR-PaC en cours. L'étude évalue RenovoGem™, une nouvelle thérapie pour le cancer du pancréas localement avancé (LAPC) utilisant la plateforme TAMP™ (Micro-perfusion transartérielle). Cette approche vise à administrer la chimiothérapie à base de gemcitabine directement sur le site tumoral, contournant potentiellement le défi de la pénétration du médicament à travers le tissu cicatriciel protecteur de la tumeur.

L'essai compare la thérapie TAMP à la chimiothérapie intraveineuse standard. L'UNMC, qui a rejoint l'étude en juin 2024, devrait aider à finaliser l'enrôlement d'ici l'année prochaine. L'étude TIGeR-PaC recrute actuellement des patients atteints de LAPC non résécables dans plusieurs sites aux États-Unis, ce qui reflète l'engagement de RenovoRx d'améliorer les résultats pour les patients atteints de cancer du pancréas difficile à traiter.

RenovoRx (Nasdaq: RNXT) hat die Aufnahme des ersten Patienten am University of Nebraska Medical Center (UNMC) für seine laufende Phase-III TIGeR-PaC-Studie bekannt gegeben. Die Studie bewertet RenovoGem™, eine neuartige Therapie für lokal fortgeschrittenen Bauchspeicheldrüsenkrebs (LAPC), unter Verwendung der TAMP™-Plattform (Transarterielle Mikropartikelsuspension). Dieser Ansatz zielt darauf ab, die Chemotherapie mit Gemcitabin direkt an die Tumorstelle zu liefern und dadurch die Herausforderung zu überwinden, dass das Medikament durch das schützende Narbengewebe des Tumors eindringt.

Die Studie vergleicht die TAMP-Therapie mit der Standard-Infusionschemotherapie. UNMC, das im Juni 2024 an der Studie teilgenommen hat, wird voraussichtlich dazu beitragen, die Enrollment bis zum nächsten Jahr abzuschließen. Die TIGeR-PaC-Studie rekrutiert derzeit Patienten mit nicht resektablem LAPC an mehreren Standorten in den USA und spiegelt RenovoRxs Engagement wider, die Ergebnisse für Patienten mit schwer behandelbarem Bauchspeicheldrüsenkrebs zu verbessern.

Positive
  • First patient enrolled at UNMC for Phase III TIGeR-PaC clinical trial
  • UNMC's participation expected to accelerate study enrollment completion
  • Innovative TAMP therapy platform aims to improve drug delivery to pancreatic tumors
  • Potential for better patient outcomes: improved survival and decreased side effects
Negative
  • None.

Insights

The enrollment of the first patient at UNMC for RenovoRx's Phase III TIGeR-PaC trial is a significant milestone. This study, evaluating RenovoGem™ for Locally Advanced Pancreatic Cancer (LAPC), could potentially revolutionize treatment approaches. The TAMP™ platform's innovative drug delivery method aims to overcome a major hurdle in pancreatic cancer treatment - the tumor's protective scar tissue. By delivering chemotherapy directly to the tumor site, it may achieve higher drug concentrations and improved efficacy.

Key points to consider:

  • UNMC's participation could accelerate trial completion, potentially by 2025.
  • If successful, this approach could offer improved survival rates and reduced side effects compared to standard intravenous chemotherapy.
  • The trial's outcome could significantly impact the $2 billion pancreatic cancer treatment market.

While promising, investors should note that Phase III trials have historically high failure rates, especially in pancreatic cancer research.

The TIGeR-PaC trial's approach is intriguing from a clinical perspective. Pancreatic cancer's dense stroma has long been a formidable barrier to effective drug delivery. RenovoRx's TAMP™ platform, by potentially bypassing this obstacle, addresses a critical unmet need in LAPC treatment.

However, several factors warrant consideration:

  • The trial's success hinges on whether intra-arterial delivery can consistently achieve superior drug concentrations in the tumor compared to systemic administration.
  • Potential vascular complications and the technical complexity of the procedure may impact its widespread adoptability if approved.
  • Long-term survival data will be crucial, as many promising pancreatic cancer therapies have shown initial promise but failed to significantly extend overall survival.

While innovative, this approach will need to demonstrate clear superiority over current standards to change clinical practice.

The initiation of patient enrollment at UNMC for RenovoRx's Phase III trial is a positive development for the company. Key financial implications include:

  • Potential acceleration of the trial timeline, possibly leading to earlier data readouts and, if successful, faster time to market.
  • Increased visibility and credibility in the oncology space, which could attract investor interest and potential partnerships.
  • If successful, RenovoGem could capture a significant portion of the pancreatic cancer market, estimated to reach $4.2 billion by 2027.

However, investors should be cautious:

  • RenovoRx is a clinical-stage company with no approved products, making it a high-risk investment.
  • The company's cash runway and potential need for future financing should be closely monitored.
  • Competition in the oncology space is fierce and larger companies are also developing novel pancreatic cancer treatments.

While promising, the company's success hinges on the trial's outcome, which is still uncertain at this stage.

Phase III clinical trial is evaluating RenovoGem™ for the treatment of Locally Advanced Pancreatic Cancer

UNMC opened enrollment of TIGeR-PaC in June 2024 and joins esteemed clinical sites throughout United States participating in the study

LOS ALTOS, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, announced today that the first patient has been enrolled at the University of Nebraska Medical Center (“UNMC”) in RenovoRx’s ongoing pivotal Phase III TIGeR-PaC clinical trial for Locally Advanced Pancreatic Cancer (LAPC).

The TIGeR-PaC study is using RenovoRx’s TAMP™ (Trans-Arterial Micro-Perfusion) therapy platform, to evaluate the Company’s first product candidate, RenovoGem, which is a drug-device combination that utilizes pressure-mediated delivery of gemcitabine (chemotherapy) across the arterial wall near the tumor site to bathe the target tumor. The study is comparing treatment with TAMP in LAPC to the current standard-of-care (systemic intravenous chemotherapy).

“Pancreatic cancer is aggressive, and difficult to detect and treat,” said Associate Professor at UNMC, Kelsey Klute, MD, Division of Oncology & Hematology Gastrointestinal Cancer, Pancreatic Cancer. “Chemotherapy given intravenously is the current standard treatment for most patients with pancreatic cancer. One of the biggest challenges in treating pancreatic cancer is that the tumor cells build a thick layer of scar tissue around the tumor, and this scar tissue makes it difficult for drugs to penetrate the tumor itself. I think this is one of the reasons that many investigational drugs tested in pancreatic cancer fail – they simply aren’t reaching the tumor at high enough concentration to have an effect. The ongoing TIGeR-PaC study is evaluating RenovoRx’s innovative targeted (intra-arterial) approach to chemotherapy delivery, which aims to deliver medicine theoretically through the layer of scar tissue directly to the tumor in the pancreas. We are hopeful that this approach will lead to better outcomes for our patients: both improved survival as well as decreased side effects. With this initial enrollment since launching our participation in the study at UNMC just a little over a month ago, I am encouraged by the interest in this important study at UNMC.”

“We are excited that UNMC has begun enrollment with their first patient in our ongoing Phase III TIGeR-PaC clinical trial,” said Leesa Gentry, Chief Clinical Officer of RenovoRx. “UNMC is the most recent clinical site to join our pivotal TIGeR-PaC clinical study. We believe UNMC will help drive enrollment of the TIGeR-PaC trial to completion next year because they treat a larger number of patients diagnosed with pancreatic cancer. We are proud to collaborate with them as they strive to provide best-in-class care and share our deep commitment to improving outcomes for patients diagnosed with difficult-to-treat tumors, like pancreatic cancer."

UNMC is the most recent clinical trial site to join the Phase III TIGeR-PaC study. The mission of the College of Medicine at the University of Nebraska Medical Center is to lead the world in transforming lives to create a healthy future for all individuals and communities through premier educational programs, innovative research, and extraordinary patient care.

The TIGeR-PaC clinical trial is currently enrolling unresectable LAPC patients at several sites across the US. To learn more about the study and the participating clinical trial sites, visit https://clinicaltrials.gov/ (NCT03257033).

About the TIGeR-PaC Clinical Trial
TIGeR-PaC is an ongoing Phase III randomized multi-center study evaluating the proprietary TAMP™ (Trans-Arterial Micro-Perfusion) therapy platform for the treatment of Locally Advanced Pancreatic Cancer (LAPC.) RenovoRx’s first product candidate using the TAMP technology, RenovoGem™, is a novel investigational oncology drug-delivery combination utilizing the Company’s FDA-cleared RenovoCath® device for the intra-arterial administration of chemotherapy, gemcitabine.

The first interim analysis in the Phase III clinical trial was completed in March 2023, with the Data Monitoring Committee recommending a continuation of the study. The TIGeR-PaC study is investigating TAMP in LAPC. The study's primary endpoint is a 6-month Overall Survival benefit with secondary endpoints including reduced side effects versus standard of care. The second interim analysis for this study will be triggered by the 52nd event, which is estimated to occur in late 2024.

About Locally Advanced Pancreatic Cancer (LAPC)
According to the American Cancer Society’s Cancer Facts & Figures 2024 and PanCAN, respectively, pancreatic cancer has a 5-year all stages combined relative survival rate of 13% (Stages I-IV) and is on track to be the second leading cause of cancer-related deaths before 2030. LAPC is diagnosed when the disease has not spread far beyond the pancreas, however, has advanced to the point where it cannot be surgically removed. LAPC is typically associated with patients in Stage 3 of the disease as determined by the TNM (tumor, nodes and metastasis) grading system.

About RenovoRx, Inc.
RenovoRx is a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug delivery platform for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx’s patented Trans-Arterial Micro-Perfusion (TAMP™) therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy’s toxicities versus systemic intravenous therapy. RenovoRx’s novel and patented approach to targeted treatment offers the potential for increased safety, tolerance, and improved efficacy. Our Phase III lead product candidate, RenovoGem™, a novel oncology drug-device combination product, is being investigated under a U.S. investigational new drug application that is regulated by the FDA’s 21 CFR 312 pathway. RenovoGem is currently being evaluated for the treatment of locally advanced pancreatic cancer (LAPC) by the Center for Drug Evaluation and Research (the drug division of FDA). RenovoGem utilizes RenovoCath®, the Company’s FDA-cleared drug-delivery device, indicated for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion.

RenovoRx is also actively exploring the use of TAMP to treat cancers beyond LAPC as well as other commercialization strategies for its technology.

RenovoRx is committed to transforming the lives of patients by delivering innovative solutions to change the current paradigm of cancer care. RenovoGem is currently under investigation for TAMP therapeutic delivery of gemcitabine and has not been approved for commercial sale.

For more information, visit www.renovorx.com. Follow RenovoRx on FacebookLinkedIn, and Twitter.

Cautionary Note Regarding Forward-Looking Statements
This press release and statements of the Company’s management made in connection therewith contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, including but not limited to statements regarding (i) our clinical trials and studies, including anticipated timing, statements regarding the potential of RenovoCath®, RenovoGem™ or TAMP™ or regarding our ongoing TIGeR-PaC Phase III clinical trial study in LAPC, (ii) the potential for our product candidates to treat or provide clinically meaningful outcomes for certain medical conditions or diseases and (iii) our efforts to expand our intellectual property. Statements that are not purely historical are forward-looking statements. The forward-looking statements contained herein are based upon our current expectations and beliefs regarding future events, many of which, by their nature, are inherently uncertain, outside of our control and involve assumptions that may never materialize or may prove to be incorrect. These may include estimates, projections and statements relating to our research and development plans, intellectual property development, clinical trials, our therapy platform, business plans, financing plans, objectives and expected operating results, which are based on current expectations and assumptions that are subject to known and unknown risks and uncertainties that may cause actual results to differ materially and adversely from those expressed or implied by these forward-looking statements. These statements may be identified using words such as “may,” “expects,” “plans,” “aims,” “anticipates,” “believes,” “forecasts,” “estimates,” “intends,” and “potential,” or the negative of these terms or other comparable terminology regarding RenovoRx’s expectations strategy, plans or intentions, although not all forward-looking statements contain these words. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, that could cause actual events to differ materially from those projected or indicated by such statements, including, among other things: (i) the risk the publication of data as described herein will not lead to any benefits for the Company; (ii) circumstances which would adversely impact our ability to efficiently utilize our cash resources on hand or raise additional funding, (iii) the timing of the initiation, progress and potential results (including the results of interim analyses) of our preclinical studies, clinical trials and our research programs; (iv) the possibility that interim results may not be predictive of the outcome of our clinical trials, which may not demonstrate sufficient safety and efficacy to support regulatory approval of our product candidate, (v) that the applicable regulatory authorities may disagree with our interpretation of the data; research and clinical development plans and timelines, and the regulatory process for our product candidates; (vi) future potential regulatory milestones for our product candidates, including those related to current and planned clinical studies; (vii) our ability to use and expand our therapy platform to build a pipeline of product candidates; (viii) our ability to advance product candidates into, and successfully complete, clinical trials; (ix) the timing or likelihood of regulatory filings and approvals; (x) our estimates of the number of patients who suffer from the diseases we are targeting and the number of patients that may enroll in our clinical trials; (xi) the commercialization potential of our product candidates, if approved; (xii) our ability and the potential to successfully manufacture and supply our product candidates for clinical trials and for commercial use, if approved; (xiii) future strategic arrangements and/or collaborations and the potential benefits of such arrangements; (xiv) our estimates regarding expenses, future revenue, capital requirements and needs for additional financing and our ability to obtain additional capital; (xv) the sufficiency of our existing cash and cash equivalents to fund our future operating expenses and capital expenditure requirements; (xvi) our ability to retain the continued service of our key personnel and to identify, and hire and retain additional qualified personnel; (xvii) the implementation of our strategic plans for our business and product candidates; (xviii) the scope of protection we are able to establish and maintain for intellectual property rights, including our therapy platform, product candidates and research programs; (xix) our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately; (xx) the pricing, coverage and reimbursement of our product candidates, if approved; and (xxi) developments relating to our competitors and our industry, including competing product candidates and therapies. Information regarding the foregoing and additional risks may be found in the section entitled “Risk Factors” in documents that we file from time to time with the Securities and Exchange Commission.

Forward-looking statements included herein are made as of the date hereof, and RenovoRx does not undertake any obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as required by law.

Contact:
KCSA Strategic Communications
Valter Pinto or Jack Perkins
T:212-896-1254
RenovoRX@KCSA.com


FAQ

What is the purpose of RenovoRx's Phase III TIGeR-PaC clinical trial for RNXT stock?

The TIGeR-PaC trial is evaluating RenovoGem™, a novel therapy for Locally Advanced Pancreatic Cancer (LAPC), comparing it to standard intravenous chemotherapy. It aims to improve drug delivery and potentially enhance patient outcomes.

How does RenovoRx's TAMP therapy differ from standard pancreatic cancer treatments?

TAMP (Trans-Arterial Micro-Perfusion) therapy delivers chemotherapy directly to the tumor site, potentially overcoming the challenge of drug penetration through the tumor's protective scar tissue, which is a common issue with standard intravenous treatments.

When is the RenovoRx (RNXT) TIGeR-PaC clinical trial expected to complete enrollment?

With the addition of the University of Nebraska Medical Center (UNMC) as a clinical site in June 2024, RenovoRx expects to complete enrollment for the TIGeR-PaC trial by next year (2025).

What potential benefits does RenovoRx's RenovoGem therapy offer for pancreatic cancer patients?

RenovoGem therapy aims to deliver higher concentrations of chemotherapy directly to pancreatic tumors, potentially leading to improved survival rates and decreased side effects compared to standard treatments.

RenovoRx, Inc.

NASDAQ:RNXT

RNXT Rankings

RNXT Latest News

RNXT Stock Data

27.60M
23.54M
1.9%
8.18%
0.3%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SAN JOSE